{"Clinical Trial ID": "NCT01998906", "Intervention": ["INTERVENTION 1:", "- HER2+ TC", "The following treatment was given to participants with HER2+ breast cancer:", "Cycles 1 to 3 (three-week cycles): trastuzumab 8 mg/kg, IV on day 1 (Cycle 1 only; 6 mg/kg in cycles 2 and 3), doxorubicin 60 mg/m^2, IV and paclitaxel 150 mg/m^2, IV on day 1 followed by 2 weeks off.", "Cycles 4-7 (three-week cycles): trastuzumab 6 mg/kg, IV, paclitaxel 175 mg/m^2, IV, day 1, followed by 2 weeks rest.", "Cycles 8 to 10 (three-week cycles): trastuzumab 6 mg/kg, IV, day 1 and cyclophosphamide 600 mg/m^2, IV, methotrexate 40 mg/m^2, IV, and 5-fluorouracil 600 mg/m^2, IV, (collectively CMF) on days 1 and 8, followed by 2 weeks off.", "Cycles 11-17 (three-week cycles): postoperatively, participants received trastuzumab 6 mg/kg IV on Day 1, followed by 2 weeks off for a maximum of 17 overall cycles with trastuzumab. Adjuvant tamoxifen, 20 mg/day was administered for up to 5 years.", "INTERVENTION 2:", "- HER2+ C", "The following treatment was given to participants with HER2+ breast cancer:", "1-3 cycles (three-week cycles): doxorubicin 60 mg/m^2, IV and paclitaxel 150 mg/m^2, IV on day 1, followed by 2 weeks rest.", "Cycles 4-7 (three-week cycles): paclitaxel 175 mg/m^2, IV, day 1, followed by 2 weeks off.", "Cycles 8 to 10 (three-week cycles): cyclophosphamide 600 mg/m^2, IV, methotrexate 40 mg/m^2, IV and 5-fluorouracil 600 mg/m^2, IV, days 1 and 8, followed by a week off."], "Eligibility": ["Incorporation criteria:", "In women, >=18 years of age, with locally advanced breast cancer.", "- Exclusion criteria:", "A prior treatment for invasive malignancy."], "Results": ["Performance measures:", "\u2022 Survival without event (EFS) - Percentage of participants with an event", "EFS was defined as the time between randomization and the date of documented recurrence or progression of disease (local, regional, remote or contralateral) or death for any cause.", "Timeline: Reference Level (BL), Presurgery: Day 1 (Cycles 1 to 7) and Days 1 and 8 (Cycles 8 to 10); Postsurgery: Day 1 (Cycles 1 to 17); every 6 months up to 60 months after the last dose of the drug under study; thereafter, every year", "Results 1:", "Title of arm/group: HER2+ TC", "- Arm/group description: Participants with HER2+ breast cancer received the following treatment:", "Cycles 1 to 3 (three-week cycles): trastuzumab 8 mg/kg, IV on day 1 (Cycle 1 only; 6 mg/kg in cycles 2 and 3), doxorubicin 60 mg/m^2, IV and paclitaxel 150 mg/m^2, IV on day 1 followed by 2 weeks off.", "Cycles 4-7 (three-week cycles): trastuzumab 6 mg/kg, IV, paclitaxel 175 mg/m^2, IV, day 1, followed by 2 weeks rest.", "Cycles 8 to 10 (three-week cycles): trastuzumab 6 mg/kg, IV, day 1 and cyclophosphamide 600 mg/m^2, IV, methotrexate 40 mg/m^2, IV, and 5-fluorouracil 600 mg/m^2, IV, (collectively CMF) on days 1 and 8, followed by 2 weeks off.", "Cycles 11-17 (three-week cycles): postoperatively, participants received trastuzumab 6 mg/kg IV on Day 1, followed by 2 weeks off for a maximum of 17 overall cycles with trastuzumab. Adjuvant tamoxifen, 20 mg/day was administered for up to 5 years.", "Total number of participants analysed: 115", "Type of measurement: Number", "Unit of measure: % of participants 40.0", "Results 2:", "Title of arm/group: HER2+ C", "- Arm/group description: Participants with HER2+ breast cancer received the following treatment:", "1-3 cycles (three-week cycles): doxorubicin 60 mg/m^2, IV and paclitaxel 150 mg/m^2, IV on day 1, followed by 2 weeks rest.", "Cycles 4-7 (three-week cycles): paclitaxel 175 mg/m^2, IV, day 1, followed by 2 weeks off.", "Cycles 8 to 10 (three-week cycles): cyclophosphamide 600 mg/m^2, IV, methotrexate 40 mg/m^2, IV and 5-fluorouracil 600 mg/m^2, IV, days 1 and 8, followed by a week off.", "Total number of participants analysed: 116", "Type of measurement: Number", "Unit of measure: % of participants 50.9"], "Adverse Events": ["Undesirable Events 1:", "Total: 18/115 (15.65%)", "* 7/115 (6.09 per cent)", "Neutropenia * 1/115 (0.87%)", "Pancytopenia * 1/115 (0.87%)", "Diarrhoea * 0/115 (0.00 %)", "Nausea * 0/115 (0.00 %)", "Stomatitis * 0/115 (0.00 %)", "Vomiting * 1/115 (0.87%)", "Asthenia * 1/115 (0.87%)", "Inflammation of mucous membranes * 0/115 (0.00 %)", "Pyrexia * 3/115 (2.61 %)", "Gastrointestinal infection * 1/115 (0.87%)", "Adverse Events 2:", "Total: 8/112 (7.14 per cent)", "Febrile neutropenia * 3/112 (2.68 %)", "Neutropenia * 2/112 (1.79%)", "Pancytopenia * 0/112 (0.00 %)", "Diarrhoea * 2/112 (1.79%)", "Nausea * 2/112 (1.79%)", "* 1/112 (0.89%)", "Vomiting * 1/112 (0.89%)", "Asthenia * 0/112 (0.00 %)", "Inflammation of mucous membranes * 1/112 (0.89%)", "Pyrexia * 0/112 (0.00 %)", "Gastrointestinal infection * 0/112 (0.00 %)"]}